Stay updated on Wild-Type Reovirus Combo for Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Wild-Type Reovirus Combo for Multiple Myeloma Clinical Trial page.

Latest updates to the Wild-Type Reovirus Combo for Multiple Myeloma Clinical Trial page
- ChecktodayChange DetectedThe completed phase 1 study record describes a combination of wild-type reovirus, carfilzomib, and dexamethasone for relapsed or refractory multiple myeloma. It includes the study design, participant criteria, measured outcomes, locations, and a related publication.SummaryDifference71%

- Check7 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedAn NIH-wide notice about terminology during a website transition was added above the error page, and the footer revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check35 days agoChange DetectedThe 403 Forbidden error page remains otherwise unchanged, while the footer’s site revision label advances from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check49 days agoChange DetectedThe page now displays a 403 Forbidden error with a minimal header and a Home link, indicating the study record is temporarily inaccessible and no detailed trial information is shown. The prior content related to the study appears unavailable due to the access restriction.SummaryDifference22%

- Check56 days agoChange DetectedRevision updated from v3.6.6 to v3.7.0, reflecting a newer site release without altering the study information or page content.SummaryDifference0.0%

Stay in the know with updates to Wild-Type Reovirus Combo for Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Wild-Type Reovirus Combo for Multiple Myeloma Clinical Trial page.